- Revenues with € 12.1 m at the level of previous year
- Earnings before interest an taxes (EBIT) of € 3.9 m (compared with € 4.5 m in twelve months in 2015)
- Net income of € 3.4 m (compared with € 6.7 m in twelve months in 2015)
- Guidance for 2017:
- Slight increase in revenues to € 16.5 m to € 17.0 m
- Stable EBIT of € 4.5 m to € 5.0 m
Bremen, January 23, 2017 - MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], a leading provider of medical imaging software, today announced its figures for the short fiscal year 2016, with the reporting period January 1 to September 30, 2016.
At € 12.1 m, revenues in 2016 were almost exactly 9/12 of previous year's revenues of € 16.0 m, which were generated in twelve months. The business with Hologic, which represents the Digital Mammography segment, increased slightly in importance, contributing 79 % to revenues. As a result the revenue share of the Other Diagnostics segment declined slightly from 22 % to 21 %.
The share of the license business fell marginally from 48 % of the total revenues in 2015 to 46 % in 2016; In return, the share of the maintenance business increased slightly from 44 % to 45 %. The share of services could be increased from 8 % to 9 % of sales.
Staff costs remained stable at € 5.5 m in nine months of 2016, compared with € 7.4 m in twelve months of 2015. Other operating expenses as well as depreciation have fallen significantly.
This results in an EBIT (earnings before interest and taxes) of € 3.9 compared to € 4.5 million in twelve months in 2015, corresponding to an increase in the EBIT margin from 28 % to 32 %.
The financial result decreased year-on-year to € -0.5 m, mainly due to the deterioration in the result from exchange rate differences.
Due to the fiscal unity no income taxes were incurred in the short fiscal year 2016. Thus, after-tax earnings amounted to € 3.4 m in the reporting period (previous year: € 6.7 m), corresponding to undiluted earnings per share of € 1.88 (previous year: € 3.76)
"2016 was also a very successful year for us economically." said Dr. Robert Hannemann, CFO of MeVis Medical Solutions AG." He added: "However, for 2017 we expect a decline of the ongoing business from new license and maintenance contracts with our existing customers." Mr. Kirchhoff, CEO of MeVis Medical Solutions AG, said: "We believe that we can more than compensate this decline in the license and maintenance business through a significant increase in development support for Hologic for the development of its own software and the one-time effect from the sale of extensive software user rights for our prototyping platform MeVisLab to Varian Medical Systems." Dr. Robert Hannemann added: "For 2017, we expect an increase in revenues to € 16.5 m to € 17.0 m, as well as a stable EBIT between € 4.5 m and € 5.0 m."
The interim financial statement for the first quarter 2017 will be published on February 21, 2017.